The background to this themed issue on neuropeptides

Julie Keeble

doi:10.1111/bph.12474

The background to this themed issue on neuropeptides

Julie Keeble^*

^*Corresponding author for this work

Institute of Pharmaceutical Science

Research output: Contribution to journal › Editorial › peer-review

1 Citation (Scopus)

Abstract

A meeting of the British Pharmacological Society in association with the European Neuropeptide Club and Americal Summer Neuropeptide Conference in June 2012 led to this themed issue on neuropetides. A wide range of neuropeptides are discussed, in various physiological and pathophysiological conditions, with respect to their upstream and downstream pathways. It is clear, at this point in time, that targeting neuropeptides has therapeutic potential in pathologies ranging from migraine to obesity. It is also clear from the reviews in this issue of the British Journal of Pharmacology that there is still so much to learn.

Original language	English
Article number	N/A
Pages (from-to)	1277-1278
Number of pages	2
Journal	British Journal of Pharmacology
Volume	170
Issue number	7
DOIs	https://doi.org/10.1111/bph.12474
Publication status	Published - Dec 2013

Keywords

CGRP
GPCR
motilin
neuropeptides
pituitary adenylyl cyclase-activating peptide
substance P
TRPV1
vasoactive intestinal peptide

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bph.12474

Cite this

@article{059a1a3a763c43aeade8b5b960cee929,

title = "The background to this themed issue on neuropeptides",

abstract = "A meeting of the British Pharmacological Society in association with the European Neuropeptide Club and Americal Summer Neuropeptide Conference in June 2012 led to this themed issue on neuropetides. A wide range of neuropeptides are discussed, in various physiological and pathophysiological conditions, with respect to their upstream and downstream pathways. It is clear, at this point in time, that targeting neuropeptides has therapeutic potential in pathologies ranging from migraine to obesity. It is also clear from the reviews in this issue of the British Journal of Pharmacology that there is still so much to learn.",

keywords = "CGRP, GPCR, motilin, neuropeptides, pituitary adenylyl cyclase-activating peptide, substance P, TRPV1, vasoactive intestinal peptide",

author = "Julie Keeble",

year = "2013",

month = dec,

doi = "10.1111/bph.12474",

language = "English",

volume = "170",

pages = "1277--1278",

journal = "British Journal of Pharmacology",

issn = "0007-1188",

publisher = "Wiley-Blackwell",

number = "7",

}

TY - JOUR

T1 - The background to this themed issue on neuropeptides

AU - Keeble, Julie

PY - 2013/12

Y1 - 2013/12

N2 - A meeting of the British Pharmacological Society in association with the European Neuropeptide Club and Americal Summer Neuropeptide Conference in June 2012 led to this themed issue on neuropetides. A wide range of neuropeptides are discussed, in various physiological and pathophysiological conditions, with respect to their upstream and downstream pathways. It is clear, at this point in time, that targeting neuropeptides has therapeutic potential in pathologies ranging from migraine to obesity. It is also clear from the reviews in this issue of the British Journal of Pharmacology that there is still so much to learn.

AB - A meeting of the British Pharmacological Society in association with the European Neuropeptide Club and Americal Summer Neuropeptide Conference in June 2012 led to this themed issue on neuropetides. A wide range of neuropeptides are discussed, in various physiological and pathophysiological conditions, with respect to their upstream and downstream pathways. It is clear, at this point in time, that targeting neuropeptides has therapeutic potential in pathologies ranging from migraine to obesity. It is also clear from the reviews in this issue of the British Journal of Pharmacology that there is still so much to learn.

KW - CGRP

KW - GPCR

KW - motilin

KW - neuropeptides

KW - pituitary adenylyl cyclase-activating peptide

KW - substance P

KW - TRPV1

KW - vasoactive intestinal peptide

U2 - 10.1111/bph.12474

DO - 10.1111/bph.12474

M3 - Editorial

SN - 0007-1188

VL - 170

SP - 1277

EP - 1278

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

IS - 7

M1 - N/A

ER -